- Sunder TR, Balsam MJ, Vengrow MI. Neurological manifestations of angioedema. Report of two cases and review of the1. Black CM. Systemic sclerosis state of the art 1995. Scand J literature. JAMA 1982;247:2005-7.Rheumatol. 1995;24:194-6.
- Pearson ME, HuV JC, Giorno RC, Panicheewa S, Claman2. Vuorio TK, Kahari VM, Lehtonen A, Vuorio EI. Fibroblast HN, Steigerwald C. Immunologic dysfunction in scleroderma:activation in scleroderma. Scand J Rheumatol 1984;13:229-37 evidence for increased mast cell releasability and HLA-DR3. Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santella positivity in the dermis. Arthritis Rheum 1988;31:672-7.M, Hammer CH, et al. Immunoregulatory disorders associated
- Farkas H, Gyeney L, Majthenyi P, Fust G, Varga L.with hereditary angioedema. I. Clinical manifestations of auto-Angioedema due to acquired C1-esterase inhibitor de? ciencyimmune disease. Allergy Clin Immunol 1986;77:749-57. in a patient with Helicobacter pylori infection. Z Gastroenterol4. Benbassat C, Schlesinger M, Luderschmidt C, Valentini G, 1999;37:513-8.Tierri G, Shoenfeld Y. The complement system and systemic
- Bruno G, Andreozzi P, Magrini L, Graf U, Santangelo G,sclerosis. Immunol Res 1993;12:312-6. Zaino S. Mast cell activation in acquired chronic urticaria-5. Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the angioedema. Sci Total Environ 2001;270:77-81.complement system in systemic sclerosis. Relationship to clin-
- Matucci-Cerinic M. Sensory neuropeptides and rheumaticical severity. Arthritis Rheum 1989;32:1262-7.
- Reimer G, Liebel G, Hornstein OP. In vitro complementdiseases. Rheum Dis Clin North Am 1993;19:975-91.
Scandinavian Journal of Rheumatology
Volume 31, 2002 - Issue 3